We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
In the latest trading session, Adma Biologics (ADMA - Free Report) closed at $9.01, marking a -1.53% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 2.91% for the day. On the other hand, the Dow registered a gain of 2.49%, and the technology-centric Nasdaq increased by 3.83%.
Heading into today, shares of the infectious disease drug developer had lost 44.81% over the past month, lagging the Medical sector's loss of 9.63% and the S&P 500's loss of 7.64%.
The investment community will be closely monitoring the performance of Adma Biologics in its forthcoming earnings report.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.96 per share and revenue of $639.74 million, which would represent changes of +60% and +25.4%, respectively, from the prior year.
Any recent changes to analyst estimates for Adma Biologics should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Adma Biologics presently features a Zacks Rank of #1 (Strong Buy).
In terms of valuation, Adma Biologics is presently being traded at a Forward P/E ratio of 9.58. This valuation marks a discount compared to its industry average Forward P/E of 17.84.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 148, positioning it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Adma Biologics (ADMA - Free Report) closed at $9.01, marking a -1.53% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 2.91% for the day. On the other hand, the Dow registered a gain of 2.49%, and the technology-centric Nasdaq increased by 3.83%.
Heading into today, shares of the infectious disease drug developer had lost 44.81% over the past month, lagging the Medical sector's loss of 9.63% and the S&P 500's loss of 7.64%.
The investment community will be closely monitoring the performance of Adma Biologics in its forthcoming earnings report.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.96 per share and revenue of $639.74 million, which would represent changes of +60% and +25.4%, respectively, from the prior year.
Any recent changes to analyst estimates for Adma Biologics should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Adma Biologics presently features a Zacks Rank of #1 (Strong Buy).
In terms of valuation, Adma Biologics is presently being traded at a Forward P/E ratio of 9.58. This valuation marks a discount compared to its industry average Forward P/E of 17.84.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 148, positioning it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.